目的:比较米氮平与盐酸帕罗西汀治疗轻中度卒中后抑郁(PSD)的临床疗效及短期不良反应发生情况。方法:选取2018年5月至2019年10月我院收治的60例轻中度PSD患者,随机分为实验组和对照组,每组30例。实验组采用米氮平治疗,对照组采取盐酸帕罗西汀治疗,比较两组患者治疗前、后汉密尔顿抑郁量表(HAMD)评分、临床有效率及短期不良反应发生情况。结果:(1) 实验组临床有效率显著高于对照组(P<0.05);治疗前两组患者HAMD评分差异无统计学意义(P>0.05),治疗1、2、4周后实验组HAMD评分均显著低于对照组(P<0.05)。(2) 实验组短期不良反应发生率显著低于对照组(P<0.05)。结论:米氮平与盐酸帕罗西汀治疗PSD均有一定效果,但米氮平见效快、疗效好,且不良反应少,可考虑在临床广泛应用。

[1] VILLA R F,FERRARI F,MORETTI A.Post-stroke depression:mechanisms and pharmacological treatment[J].Pharmacol Ther,2018,184:131-144.
[2] SCHOTTKE H,GERKE L,DUSING R,et al.Post-stroke depression and functional impairments-a 3-year prospective study[J].Compr Psychiatry,2020,99:152171.
[3] KALLIO M E.Neuropsychiatric outcomes after stroke[J].Lancet Neurol,2014,13(12):1168.
[4] CAI W,MUELLER C,LI Y J,et al.Post stroke depression and risk of stroke recurrence and mortality:a systematic review and meta-analysis[J].Ageing Res Rev,2019,50:102-109.
[5] ROBINSON R G,JORGE R E.Post-stroke depression:a review[J].Am J Psychiatry,2016,173(3):221-231.
[6] KUPFER D J,KUHL E A,WULSIN L.Psychiatry's integration with medicine:the role of DSM-5[J].Annu Rev Med,2013,64:385-392.
[7] 王少石,周新雨,朱春燕.卒中后抑郁临床实践的中国专家共识[J].中国卒中杂志,2016,11(8):685-693.
[8] LIN F,GU Y,WU Y,et al.Effect of music therapy derived from the five elements in Traditional Chinese Medicine on post-stroke depression[J].J Tradit Chin Med,2017,37(5):675-680.
[9] BLAND J M,ALTMAN D G.Multiple significance tests:the Bonferroni method[J].BMJ,1995,310(6973):170.
[10] BENJAMIN E J,VIRANI S S,CALLAWAY C W,et al.Heart disease and stroke statistics-2018 update:a report from the American Heart Association[J].Circulation,2018,137(12):e67-e492.
[11] YANG G,WANG Y,ZENG Y,et al.Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010[J].Lancet,2013,381(9882):1987-2015.
[12] DALYS G B D,COLLABORATORS H.Global,regional,and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2018,392(10159):1859-1922.
[13] FEIGIN V L,NORRVING B,MENSAH G A.Global burden of stroke[J].Circ Res,2017,120(3):439-448.
[14] AYERBE L,AYIS S,CRICHTON S,et al.The natural history of depression up to 15 years after stroke:the South London Stroke Register[J].Stroke,2013,44(4):1105-1110.
[15] STEIN L A,GOLDMANN E,ZAMZAM A,et al.Association between anxiety,depression,and post-traumatic stress disorder and outcomes after ischemic stroke[J].Front Neurol,2018,9:890.
[16] BLOCHL M,MEISSNER S,NESTLER S.Does depression after stroke negatively influence physical disability?A systematic review and meta-analysis of longitudinal studies[J].J Affect Disord,2019,247:45-56.
[17] NARUSHIMA K,KOSIER J T,ROBINSON R G.Preventing poststroke depression:a 12-week double-blind randomized treatment trial and 21-month follow-up[J].J Nerv Ment Dis,2002,190(5):296-303.
[18] DANILOV D S.A 70-year history of tricyclic antidepressants[J].Zh Nevrol Psikhiatr Im S S Korsakova,2019,119(12):115-123.
[19] SPALLETTA G,CALTAGIRONE C.Sertraline treatment of post-stroke major depression:an open study in patients with moderate to severe symptoms[J].Funct Neurol,2003,18(4):227-232.
[20] TORRIGIANI G.Clinical experience with a new drug of the antidepressive series:phenelzine[J].Clin Ter,1959,17:382-387.
[21] HORVATH S,KARANYI Z,HARCOS P,et al.Clinical effectiveness and safety of paroxetine in post-stroke depression:results from a phase 4,open label,multicenter clinical trial with 26 weeks of follow-up[J].Orv Hetil,2006,147(50):2397-2404.
[22] FANG Y,YUAN C,XU Y,et al.Comparisons of the efficacy and tolerability of extended-release venlafaxine,mirtazapine,and paroxetine in treatment-resistant depression:a double-blind,randomized pilot study in a Chinese population[J].J Clin Psychopharmacol,2010,30(4):357-364.
[23] QIN B,CHEN H,GAO W,et al.Efficacy,acceptability,and tolerability of antidepressant treatments for patients with post-stroke depression:a network meta-analysis[J].Braz J Med Biol Res,2018,51(7):e7218.
[24] CROOM K F,PERRY C M,PLOSKER G L.Mirtazapine:a review of its use in major depression and other psychiatric disorders[J].CNS Drugs,2009,23(5):427-452.
[25] WEEN J E.Prophylactic mirtazapine may help to prevent post-stroke depression in people with good cognitive function[J].Evid Based Ment Health,2005,8(3):74.
[26] LI X,ZHANG C.Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression:a network meta-analysis[J].J Affect Disord,2020,266:540-548.
[27] BENKERT O,SZEGEDI A,KOHNEN R.Mirtazapine compared with paroxetine in major depression[J].J Clin Psychiatry,2000,61(9):656-663.
[28] CIPRIANI A,FURUKAWA T A,SALANTI G,et al.Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder:a systematic review and network meta-analysis[J].Lancet,2018,391(10128):1357-1366.
[29] CHEN C,SHAN W.Pharmacological and non-pharmacological treatments for major depressive disorder in adults:a systematic review and network meta-analysis[J].Psyachiatry Res,2019,281:112595.